Compliance to recommended liver function monitoring in patients on statin therapy

Heather Leaver, Tiong Keng Lim, Philip Thomson, Joanne Leaver, Anna M. J. Choy, Chim C. Lang

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Product information and national guidelines consistently recommend the estimation of serum alanine aminotranferase (ALT) before and after approximately 3 months as part of risk management following initiation of statin therapy. The aim of this study was to determine compliance to the recommendations for monitoring ALT in patients initiated on statin therapy. The prevalence of abnormal serum ALT levels was also evaluated and compared with current data. We performed a retrospective observational audit of the Medicine's Monitoring Unit (MEMO) prescribing record-linkage database, which includes evidence of prescribing and biochemistry results of all patients in Tayside, Scotland. We examined patients with first-time statin prescriptions and evaluated all laboratory liver function tests recorded before and after prescriptions from 1st January 2002 to 31st December 2002. Of the 5717 patients identified, 54% were male and the subjects had a mean age of 62 +/- 14 standard deviation (SD) years. The prescriptions yielded five types of statin and included the start date, dose, and number of tablets. In total, 1455 (25%) patients had no biochemistry data at all from the year 2002, and despite the 75% of patients who had an ALT measurement, over 90% of patients did not follow the current recommendations. The prevalence of elevated transaminases was consistent with published data in that significant elevation occurred in 1.9% of subjects. Adherence to the recommended laboratory monitoring for patients first prescribed with statin therapy is low in Tayside. Adverse drug reactions need to be more closely monitored by all healthcare professionals involved in prescribing. Monitoring can highlight abnormalities and therefore reduce potentially damaging effects.

    Original languageEnglish
    Pages (from-to)96-100
    Number of pages5
    JournalCardiovascular Therapeutics
    Volume27
    Issue number2
    DOIs
    Publication statusPublished - 2009

    Keywords

    • Adverse drug reactions
    • Drug safety monitoring
    • Hepatoxicity
    • Statins
    • ADVERSE DRUG EVENTS
    • PRIMARY-CARE
    • SAFETY
    • BENEFITS
    • RISKS
    • TESTS
    • YIELD

    Cite this

    Leaver, Heather ; Lim, Tiong Keng ; Thomson, Philip ; Leaver, Joanne ; Choy, Anna M. J. ; Lang, Chim C. / Compliance to recommended liver function monitoring in patients on statin therapy. In: Cardiovascular Therapeutics. 2009 ; Vol. 27, No. 2. pp. 96-100.
    @article{6f291e8ef8934785adeeb74d9f5efcbe,
    title = "Compliance to recommended liver function monitoring in patients on statin therapy",
    abstract = "Product information and national guidelines consistently recommend the estimation of serum alanine aminotranferase (ALT) before and after approximately 3 months as part of risk management following initiation of statin therapy. The aim of this study was to determine compliance to the recommendations for monitoring ALT in patients initiated on statin therapy. The prevalence of abnormal serum ALT levels was also evaluated and compared with current data. We performed a retrospective observational audit of the Medicine's Monitoring Unit (MEMO) prescribing record-linkage database, which includes evidence of prescribing and biochemistry results of all patients in Tayside, Scotland. We examined patients with first-time statin prescriptions and evaluated all laboratory liver function tests recorded before and after prescriptions from 1st January 2002 to 31st December 2002. Of the 5717 patients identified, 54{\%} were male and the subjects had a mean age of 62 +/- 14 standard deviation (SD) years. The prescriptions yielded five types of statin and included the start date, dose, and number of tablets. In total, 1455 (25{\%}) patients had no biochemistry data at all from the year 2002, and despite the 75{\%} of patients who had an ALT measurement, over 90{\%} of patients did not follow the current recommendations. The prevalence of elevated transaminases was consistent with published data in that significant elevation occurred in 1.9{\%} of subjects. Adherence to the recommended laboratory monitoring for patients first prescribed with statin therapy is low in Tayside. Adverse drug reactions need to be more closely monitored by all healthcare professionals involved in prescribing. Monitoring can highlight abnormalities and therefore reduce potentially damaging effects.",
    keywords = "Adverse drug reactions, Drug safety monitoring, Hepatoxicity, Statins, ADVERSE DRUG EVENTS, PRIMARY-CARE, SAFETY, BENEFITS, RISKS, TESTS, YIELD",
    author = "Heather Leaver and Lim, {Tiong Keng} and Philip Thomson and Joanne Leaver and Choy, {Anna M. J.} and Lang, {Chim C.}",
    year = "2009",
    doi = "10.1111/j.1755-5922.2009.00082.x",
    language = "English",
    volume = "27",
    pages = "96--100",
    journal = "Cardiovascular Therapeutics",
    issn = "1755-5914",
    publisher = "Wiley",
    number = "2",

    }

    Compliance to recommended liver function monitoring in patients on statin therapy. / Leaver, Heather; Lim, Tiong Keng; Thomson, Philip; Leaver, Joanne; Choy, Anna M. J.; Lang, Chim C.

    In: Cardiovascular Therapeutics, Vol. 27, No. 2, 2009, p. 96-100.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Compliance to recommended liver function monitoring in patients on statin therapy

    AU - Leaver, Heather

    AU - Lim, Tiong Keng

    AU - Thomson, Philip

    AU - Leaver, Joanne

    AU - Choy, Anna M. J.

    AU - Lang, Chim C.

    PY - 2009

    Y1 - 2009

    N2 - Product information and national guidelines consistently recommend the estimation of serum alanine aminotranferase (ALT) before and after approximately 3 months as part of risk management following initiation of statin therapy. The aim of this study was to determine compliance to the recommendations for monitoring ALT in patients initiated on statin therapy. The prevalence of abnormal serum ALT levels was also evaluated and compared with current data. We performed a retrospective observational audit of the Medicine's Monitoring Unit (MEMO) prescribing record-linkage database, which includes evidence of prescribing and biochemistry results of all patients in Tayside, Scotland. We examined patients with first-time statin prescriptions and evaluated all laboratory liver function tests recorded before and after prescriptions from 1st January 2002 to 31st December 2002. Of the 5717 patients identified, 54% were male and the subjects had a mean age of 62 +/- 14 standard deviation (SD) years. The prescriptions yielded five types of statin and included the start date, dose, and number of tablets. In total, 1455 (25%) patients had no biochemistry data at all from the year 2002, and despite the 75% of patients who had an ALT measurement, over 90% of patients did not follow the current recommendations. The prevalence of elevated transaminases was consistent with published data in that significant elevation occurred in 1.9% of subjects. Adherence to the recommended laboratory monitoring for patients first prescribed with statin therapy is low in Tayside. Adverse drug reactions need to be more closely monitored by all healthcare professionals involved in prescribing. Monitoring can highlight abnormalities and therefore reduce potentially damaging effects.

    AB - Product information and national guidelines consistently recommend the estimation of serum alanine aminotranferase (ALT) before and after approximately 3 months as part of risk management following initiation of statin therapy. The aim of this study was to determine compliance to the recommendations for monitoring ALT in patients initiated on statin therapy. The prevalence of abnormal serum ALT levels was also evaluated and compared with current data. We performed a retrospective observational audit of the Medicine's Monitoring Unit (MEMO) prescribing record-linkage database, which includes evidence of prescribing and biochemistry results of all patients in Tayside, Scotland. We examined patients with first-time statin prescriptions and evaluated all laboratory liver function tests recorded before and after prescriptions from 1st January 2002 to 31st December 2002. Of the 5717 patients identified, 54% were male and the subjects had a mean age of 62 +/- 14 standard deviation (SD) years. The prescriptions yielded five types of statin and included the start date, dose, and number of tablets. In total, 1455 (25%) patients had no biochemistry data at all from the year 2002, and despite the 75% of patients who had an ALT measurement, over 90% of patients did not follow the current recommendations. The prevalence of elevated transaminases was consistent with published data in that significant elevation occurred in 1.9% of subjects. Adherence to the recommended laboratory monitoring for patients first prescribed with statin therapy is low in Tayside. Adverse drug reactions need to be more closely monitored by all healthcare professionals involved in prescribing. Monitoring can highlight abnormalities and therefore reduce potentially damaging effects.

    KW - Adverse drug reactions

    KW - Drug safety monitoring

    KW - Hepatoxicity

    KW - Statins

    KW - ADVERSE DRUG EVENTS

    KW - PRIMARY-CARE

    KW - SAFETY

    KW - BENEFITS

    KW - RISKS

    KW - TESTS

    KW - YIELD

    U2 - 10.1111/j.1755-5922.2009.00082.x

    DO - 10.1111/j.1755-5922.2009.00082.x

    M3 - Article

    VL - 27

    SP - 96

    EP - 100

    JO - Cardiovascular Therapeutics

    JF - Cardiovascular Therapeutics

    SN - 1755-5914

    IS - 2

    ER -